Search results
Results from the WOW.Com Content Network
The treatment of latent tuberculosis infection (LTBI) is essential to controlling and eliminating TB by reducing the risk that TB infection will progress to disease. Latent tuberculosis will convert to active tuberculosis in 10% of cases (or more in cases of immune compromised patients).
Tuberculosis (TB), also known colloquially as the "white death", or historically as consumption, [7] is a contagious disease usually caused by Mycobacterium tuberculosis (MTB) bacteria. [1] Tuberculosis generally affects the lungs , but it can also affect other parts of the body. [ 1 ]
The current clinical classification system for tuberculosis (TB) is based on the pathogenesis of the disease. [1] Health care providers should comply with local laws and regulations requiring the reporting of TB. All persons with class 3 or class 5 TB should be reported promptly to the local health department. [2]
Of 200 immigrants tested for tuberculosis over the last year, 8 in 10 had the latent — that's to say, not contagious — version of the disease.
According to the US guidelines, latent tuberculosis infection diagnosis and treatment is considered for any BCG-vaccinated person whose skin test is 10 mm or greater, if any of these circumstances are present: [citation needed] Was in contact with another person with infectious TB; Was born or has lived in a high TB prevalence country
Management of tuberculosis refers to techniques and procedures utilized for treating tuberculosis (TB), or simply a treatment plan for TB. The medical standard for active TB is a short course treatment involving a combination of isoniazid , rifampicin (also known as Rifampin), pyrazinamide , and ethambutol for the first two months.
Most people affected by TB do not have symptoms, and the disease is not active. This is called latent tuberculosis. [1] However, about 10% of latent infections progress to active disease, which, if left untreated, kills about half of those affected. [1]
The Quantiferon-TB Gold test (QFT-G) is a whole-blood test for use as an aid in diagnosing Mycobacterium tuberculosis infection, including latent tuberculosis infection (LTBI) and tuberculosis (TB) disease. [15] This test was approved by the U.S. Food and Drug Administration (FDA) in 2005.